Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118389 | 0.92 | PTGS2 (0.54) | PTGS2ALDH1A1MEN1KMT2AALOX15 | |
| SCHEMBL3102148 | 0.89 | PTGS2 (0.53) | PTGS2CA4CA2 | |
| SCHEMBL14292740 | 0.86 | CA4 (0.54) | PTGS2ALDH1A1MEN1KMT2AALOX15 | |
| SCHEMBL3101658 | 0.85 | PTGS2 (0.54) | PTGS2CA2 | |
| SCHEMBL3106608 | 0.85 | PTGS2 (0.54) | PTGS2SMN1; SMN2 | |
| SCHEMBL3113061 | 0.84 | CA4 (0.53) | PTGS2ALDH1A1MEN1KMT2AALOX15 | |
| SCHEMBL3115632 | 0.82 | CA9 (0.53) | PTGS2ALDH1A1MEN1KMT2AALOX15 | |
| SCHEMBL3117954 | 0.80 | PTGS2 (0.57) | PTGS2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13108805 | 0.76 | CA2 (0.48) | PTGS2ALDH1A1MEN1KMT2AALOX15 | |
| SCHEMBL3109959 | 0.76 | CA2 (0.49) | MEN1KMT2AALOX15SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | PTGS2 47/4885ALDH1A1 1198/4885MEN1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.